Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 ...
Sponsored by Moderna, the trial evaluates the efficacy and safety of a norovirus vaccine called mRNA-1403. There are currently no licensed norovirus vaccines in use anywhere in the world. The phase 3 ...
The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in adults against globally prevalent norovirus genotypes, according to ...
Credit: New Africa via Shutterstock. A Phase III clinical trial is being launched in the UK to investigate Moderna’s norovirus vaccine mRNA-1403. This is the first vaccine trialled in the UK to target ...
The UK and NHS could help license the world’s first norovirus vaccine as a groundbreaking clinical trial is set to begin over the next two weeks to evaluate a new mRNA vaccine. Including at 27 NHS ...
However, the trial, sponsored by Moderna, a pharmaceutical and biotechnology company, will evaluate the efficacy, safety and immunogenicity of an investigational norovirus vaccine, mRNA-1403.
However, the trial, sponsored by Moderna, a pharmaceutical and biotechnology company, will evaluate the efficacy, safety and immunogenicity of an investigational norovirus vaccine, mRNA-1403. READ ...
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine ...
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomised, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback